Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today its financial results for the first quarter ended March 31, 2022.
Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer commented, “During the first quarter we progressed further on our journey to deliver leading biodegradable packaging solutions for a variety of in-demand customer applications. PHA revenues nearly doubled year-over-year, driving total revenues up 12% to $14.7 million. We were also able to continue negotiating various development and supply agreements with customers. Of note is the recent announcement of the expansion of our partnership with Kemira to commercialize barrier coatings for paper products such as coffee cups. We were also pleased to further scale production at Phase I of our Kentucky facility while ensuring Phase II construction advanced in accordance with our plan to bring the facility online and begin to scale up by the end of the second quarter. As we move through 2022, our continued expansion of production capacity, application development expertise, contracted revenue streams and future efficiencies of scale should continue to shape our bright path forward as an increasing number of companies evaluate solutions to maintain their ESG commitments using our superior biodegradable alternatives.”
First Quarter 2022 Financial Highlights
(1) | An explanation of non-GAAP measures disclosed in this release and a reconciliation of these non-GAAP results to comparable GAAP measures are included in the “Non-GAAP Financial Measures” section of the release. |
Capital Structure and Cash Balance
At March 31, 2022, the Company reported total debt outstanding of $261.7 million, net of $10.1 million of unamortized debt issuance costs, and includes approximately $21.0 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven in 2026. At the end of the first quarter, cash and cash equivalents were $210.0 million.
Outlook
Danimer continues to focus on making disciplined investments in its operational platform and infrastructure that will allow it to capture the significant opportunity for its products. The Company expects full year 2022 will be another year of investment, with an intense focus on getting its PHA-based business to profitability.
For the full year 2022, the Company is introducing its outlook for Adjusted EBITDA to be in the range of $(45) million to $(35) million, compared to $(22.6) million in 2021. The Company expects its Kentucky facility to have a favorable year-over-year impact and to turn profitable as it increases its PHA-based revenues and drives operational efficiencies. The improved profitability from PHA-based revenues is expected to be more than offset by lower PLA-based revenue, a full year of prior SG&A and R&D investments to support growth, as well as a full year of consolidated costs from Danimer Catalytic Technologies acquired in August 2021. The Company expects full year capital expenditures to be in the range of $190 million to $200 million, inclusive of capitalized interest and internal labor and overhead, and have a year-end cash balance in excess of $50 million.
Looking beyond 2022, the Company expects its PHA-based revenues to drive a significant increase in the Company’s overall profitability. The Company remains confident in its ability to execute against its objectives with a prudent focus on profitability and cash management.
Webcast, Conference Call and 10-Q Filing
The Company will host a webcast and conference call on Tuesday, May 10, 2022, at 5:00 p.m. Eastern time to review first quarter of 2022 results, discuss recent events and conduct a question-and-answer session. The live webcast will be available at www.danimerscientific.com in the Investor Relations section. The conference call will also be accessible by dialing 1-877-407-9208 (Domestic) and 1-201-493-6784 (International). A replay of the webcast will be available on the Company’s website.
About Danimer Scientific
Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 430 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit www.DanimerScientific.com.
Forward‐Looking Statements
Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our expectations for full year 2022 capital expenditures and Adjusted EBITDA. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.
Danimer Scientific, Inc. Condensed Consolidated Balance Sheets (Unaudited) | ||||||||
|
| March 31, |
|
| December 31, |
| ||
(in thousands, except share and per share data) |
| 2022 |
|
| 2021 |
| ||
Assets: |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 210,045 |
|
| $ | 286,487 |
|
Accounts receivable, net |
|
| 18,825 |
|
|
| 17,149 |
|
Other receivables, net |
|
| 1,378 |
|
|
| 3,836 |
|
Inventories, net |
|
| 28,230 |
|
|
| 24,573 |
|
Prepaid expenses and other current assets |
|
| 4,059 |
|
|
| 4,737 |
|
Contract assets |
|
| 4,305 |
|
|
| 3,576 |
|
Total current assets |
|
| 266,842 |
|
|
| 340,358 |
|
|
|
|
|
|
|
| ||
Property, plant and equipment, net |
|
| 364,635 |
|
|
| 316,181 |
|
Intangible assets, net |
|
| 83,578 |
|
|
| 84,659 |
|
Goodwill |
|
| 62,663 |
|
|
| 62,649 |
|
Right-of-use assets |
|
| 19,179 |
|
|
| 19,240 |
|
Leverage loans receivable |
|
| 13,408 |
|
|
| 13,408 |
|
Restricted cash |
|
| 480 |
|
|
| 481 |
|
Loan fees |
|
| 1,452 |
|
|
| 1,397 |
|
Other assets |
|
| 228 |
|
|
| 224 |
|
Total assets |
| $ | 812,465 |
|
| $ | 838,597 |
|
|
|
|
|
|
|
| ||
Liabilities and Stockholders' Equity: |
|
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
|
| ||
Accounts payable |
| $ | 17,076 |
|
| $ | 20,790 |
|
Accrued liabilities |
|
| 14,042 |
|
|
| 18,777 |
|
Unearned revenue and contract liabilities |
|
| - |
|
|
| 214 |
|
Current portion of lease liability |
|
| 3,337 |
|
|
| 3,337 |
|
Current portion of long-term debt, net |
|
| 218 |
|
|
| 357 |
|
Total current liabilities |
|
| 34,673 |
|
|
| 43,475 |
|
|
|
|
|
|
|
| ||
Private warrants liability |
|
| 4,583 |
|
|
| 9,578 |
|
Long-term lease liability, net |
|
| 22,554 |
|
|
| 22,693 |
|
Long-term debt, net |
|
| 261,459 |
|
|
| 260,934 |
|
Deferred income taxes |
|
| 723 |
|
|
| 1,014 |
|
Other long-term liabilities |
|
| 526 |
|
|
| 638 |
|
Total liabilities |
| $ | 324,518 |
|
| $ | 338,332 |
|
|
|
|
|
|
|
| ||
Stockholders' equity: |
|
|
|
|
|
| ||
Common stock, $0.0001 par value; 200,000,000 shares authorized: 100,760,215 and 100,687,820 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively |
| $ | 10 |
|
| $ | 10 |
|
Additional paid-in capital |
|
| 633,213 |
|
|
| 619,145 |
|
Accumulated deficit |
|
| (145,276 | ) |
|
| (118,890 | ) |
Total stockholders’ equity |
|
| 487,947 |
|
|
| 500,265 |
|
Total liabilities and stockholders’ equity |
| $ | 812,465 |
|
| $ | 838,597 |
|
Danimer Scientific, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||
|
| Three Months Ended March 31, |
| |||||
(in thousands, except share and per share data) |
| 2022 |
|
| 2021 |
| ||
Revenue: |
|
|
|
|
|
| ||
Products |
| $ | 13,216 |
|
| $ | 11,024 |
|
Services |
|
| 1,527 |
|
|
| 2,157 |
|
Total revenue |
|
| 14,743 |
|
|
| 13,181 |
|
|
|
|
|
|
|
| ||
Costs and expenses: |
|
|
|
|
|
| ||
Cost of revenue |
|
| 16,065 |
|
|
| 11,725 |
|
Selling, general and administrative |
|
| 22,236 |
|
|
| 10,120 |
|
Research and development |
|
| 7,131 |
|
|
| 2,619 |
|
Total costs and expenses |
|
| 45,432 |
|
|
| 24,464 |
|
Loss from operations |
|
| (30,689 | ) |
|
| (11,283 | ) |
|
|
|
|
|
|
| ||
Nonoperating income (expense): |
|
|
|
|
|
| ||
Gain on remeasurement of private warrants |
|
| 4,995 |
|
|
| (80,697 | ) |
Interest, net |
|
| (992 | ) |
|
| (148 | ) |
Loss on loan extinguishment |
|
| - |
|
|
| (2,604 | ) |
Other expense, net |
|
| 9 |
|
|
| (2 | ) |
Total nonoperating income (expense) |
|
| 4,012 |
|
|
| (83,451 | ) |
Loss before income taxes |
|
| (26,677 | ) |
|
| (94,734 | ) |
Income taxes |
|
| 291 |
|
|
| - |
|
Net loss |
| $ | (26,386 | ) |
| $ | (94,734 | ) |
|
|
|
|
|
|
| ||
Basic and diluted net loss per share |
| $ | (0.26 | ) |
| $ | (1.12 | ) |
|
|
|
|
|
|
| ||
Weighted average number of shares used to compute |
|
|
|
|
|
| ||
Basic and diluted net loss per share |
|
| 100,728,366 |
|
|
| 84,708,137 |
|
Danimer Scientific, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||||
|
| Three Months Ended | |||||||
|
| March 31, | |||||||
(in thousands) |
| 2022 |
|
| 2021 |
|
| ||
Cash flows from operating activities: |
|
|
|
|
|
|
| ||
Net loss |
| $ | (26,386 | ) |
| $ | (94,734 | ) |
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
| ||
(Gain) loss on remeasurement of private warrants |
|
| (4,995 | ) |
|
| 80,697 |
|
|
Stock-based compensation |
|
| 13,750 |
|
|
| 6,665 |
|
|
Depreciation and amortization |
|
| 4,259 |
|
|
| 2,100 |
|
|
Inventory reserves |
|
| 1,056 |
|
|
| - |
|
|
Deferred income taxes |
|
| (291 | ) |
|
| - |
|
|
Loss on write-off of deferred loan costs |
|
| - |
|
|
| 1,900 |
|
|
Amortization of debt issuance costs and debt discounts |
|
| 572 |
|
|
| 82 |
|
|
Amortization of right-of-use assets and lease liability |
|
| (77 | ) |
|
| 41 |
|
|
Other |
|
| 612 |
|
|
| 38 |
|
|
Changes in operating assets and liabilities, net of effects of acquisition: |
|
|
|
|
|
|
| ||
Accounts receivable, net |
|
| (2,272 | ) |
|
| (3,529 | ) |
|
Other receivables |
|
| 2,458 |
|
|
| 20 |
|
|
Inventories, net |
|
| (4,713 | ) |
|
| (3,204 | ) |
|
Prepaid expenses and other current assets |
|
| 678 |
|
|
| (1,498 | ) |
|
Contract assets |
|
| (729 | ) |
|
| - |
|
|
Other assets |
|
| (4 | ) |
|
| 125 |
|
|
Accounts payable |
|
| 725 |
|
|
| (669 | ) |
|
Accrued and other long-term liabilities |
|
| (2,034 | ) |
|
| (2,123 | ) |
|
Unearned revenue and contract liabilities |
|
| (214 | ) |
|
| (119 | ) |
|
Net cash used in operating activities |
|
| (17,605 | ) |
|
| (14,208 | ) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
| ||
Purchases of property, plant and equipment |
|
| (58,902 | ) |
|
| (23,893 | ) |
|
Acquisition of Novomer, net of cash acquired |
|
| (14 | ) |
|
| - |
|
|
Net cash used in investing activities |
|
| (58,916 | ) |
|
| (23,893 | ) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
| ||
Proceeds from long-term debt |
|
| - |
|
|
| 120 |
|
|
Cash paid for debt issuance costs |
|
| (196 | ) |
|
| (25 | ) |
|
Proceeds from exercise of stock options |
|
| 164 |
|
|
| 1,191 |
|
|
Proceeds from employee stock purchase plan |
|
| 209 |
|
|
| - |
|
|
Principal payments on long-term debt |
|
| (44 | ) |
|
| (27,037 | ) |
|
Cost related to warrants |
|
| (55 | ) |
|
| - |
|
|
Proceeds from issuance of common stock, net of issuance costs |
|
| - |
|
|
| (815 | ) |
|
Net cash provided by (used in) financing activities |
|
| 78 |
|
|
| (26,566 | ) |
|
Net decrease in cash and cash equivalents and restricted cash |
|
| (76,443 | ) |
|
| (64,667 | ) |
|
Cash and cash equivalents and restricted cash-beginning of period |
|
| 286,968 |
|
|
| 379,897 |
|
|
Cash and cash equivalents and restricted cash-end of period |
| $ | 210,525 |
|
| $ | 315,230 |
|
|
|
|
|
|
|
|
|
| ||
Supplemental cash flow information: |
|
|
|
|
|
|
| ||
Cash paid for interest |
| $ | 420 |
|
| $ | 130 |
|
|
Cash paid for operating leases |
| $ | 885 |
|
| $ | 798 |
|
|
Supplemental non-cash disclosure: |
|
|
|
|
|
|
| ||
Changes in accounts payable and accrued liabilities related to purchase of property, plant and equipment |
| $ | 7,251 |
|
| $ | 952 |
|
|
Non-GAAP Financial Measures
This press release includes the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted EBITDAR”, “Adjusted Gross Profit” and "Adjusted Gross Margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.
Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer’s business, as described below.
Adjusted EBITDAR is defined as Adjusted EBITDA plus rent expense.
Adjusted Gross Profit is defined as Gross Profit plus depreciation, PLA additive inventory reserve, stock-based compensation and rent expense.
Adjusted Gross Margin is defined as Adjusted Gross Profit divided by total revenue.
Danimer believes that each of Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin is useful to investors in evaluating the Company’s performance because each measure considers the performance of the Company’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.
Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer’s industry may define Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin exclude certain financial information that some may consider important in evaluating Danimer’s performance.
Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted EBITDAR, Adjusted Gross Profit and Adjusted Gross Margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer’s operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Forward-looking non-GAAP financial measures are presented without reconciliations to GAAP measures because the GAAP financial measures are not accessible on a forward-looking basis, and reconciling information is not available without unreasonable effort due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Danimer Scientific, Inc. Reconciliation of Adjusted EBITDAR and Adjusted EBITDA to Net Loss (Unaudited) | ||||||||
|
| Three Months Ended |
| |||||
|
| 2022 |
|
| 2021 |
| ||
|
|
|
|
|
|
| ||
Net loss |
| $ | (26,386 | ) |
| $ | (94,734 | ) |
Income tax expense (benefit) |
|
| (291 | ) |
|
| - |
|
Interest expense, net |
|
| 992 |
|
|
| 148 |
|
Depreciation and amortization |
|
| 4,259 |
|
|
| 2,100 |
|
PLA additive inventory reserve |
|
| 1,016 |
|
|
| - |
|
(Gain) loss on remeasurement of private warrants |
|
| (4,995 | ) |
|
| 80,697 |
|
Stock-based compensation |
|
| 13,700 |
|
|
| 6,665 |
|
Loss on debt extinguishment |
|
| - |
|
|
| 2,604 |
|
Litigation and other legal related |
|
| 760 |
|
|
| - |
|
Public company transition costs |
|
| 350 |
|
|
| 207 |
|
Other expense, net |
|
| (9 | ) |
|
| 2 |
|
Adjusted EBITDA (1) |
| $ | (10,604 | ) |
| $ | (2,311 | ) |
Rent |
|
| 887 |
|
|
| 725 |
|
Adjusted EBITDAR (1) |
| $ | (9,717 | ) |
| $ | (1,585 | ) |
|
|
|
|
|
|
| ||
(1) May not foot due to rounding. |
|
|
|
|
|
|
Reconciliation of Adjusted Gross Profit to Gross Profit (Unaudited) | ||||||||
|
| Three Months Ended |
| |||||
|
| 2022 |
|
| 2021 |
| ||
|
|
|
|
|
|
| ||
Total revenue |
| $ | 14,743 |
|
| $ | 13,181 |
|
Cost of revenue |
|
| 16,065 |
|
|
| 11,725 |
|
Gross Profit |
|
| (1,322 | ) |
|
| 1,456 |
|
PLA additive inventory reserve |
|
| 1,016 |
|
|
| - |
|
Depreciation |
|
| 2,227 |
|
|
| 1,839 |
|
Rent |
|
| 628 |
|
|
| 530 |
|
Stock-based compensation |
|
| 29 |
|
|
| 26 |
|
Adjusted Gross Profit (1) |
| $ | 2,578 |
|
| $ | 3,851 |
|
|
|
|
|
|
|
| ||
Adjusted Gross Margin |
|
| 17.5 | % |
|
| 29.2 | % |
|
|
|
|
|
|
| ||
(1) May not foot due to rounding. |
|
|
|
|
|
|
Last Trade: | US$3.05 |
Daily Change: | 0.51 20.08 |
Daily Volume: | 533,862 |
Market Cap: | US$9.210M |
November 19, 2024 September 26, 2024 August 08, 2024 |
GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MOREElse Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS